Immuno-Oncology

Product Name: Format/SizeDescriptionsDownload
Immuno-Oncology Library11346 compounds
For cherry-picking
Update: 2016-11
The file contains all available Immuno-Oncology compounds selected from ourSignature & BioDesign Libraries.For more information, please download >>>sdf-icon pdf-icon
SL#021
IDO1 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
By utilizing a combination of scaffold hopping and structure-based design strategies ASINEX has developed a library of small molecules for IDO1 drug discovery. Selected compounds have shown significant IDO1 inhibitory activity in vitro as measured in the enzymatic biochemical assays. For more information, please download >>>sdf-icon pdf-icon
SL#026
IRAK4 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASINEX has created a series of IRAK4-oriented compounds by combining the IRAK4 hinge binding motif with proprietary natural product-like fragments. Several compounds from this library were screened against IRAK4 kinase in vitro and showed sub-uM IC50. Sunitinib was also included in the library as a reference compound. For more information, please download >>>sdf-icon pdf-icon
SL#033
PD1/PD-L1 inhibitors
80 compounds
Pre-Plated Set
Release: 2016
ASIENX has designed a set of novel small molecule probes that can be used for exploration of PD-1/PD-L1 signaling pathway. For more information, please download >>>sdf-icon pdf-icon

 

You may also like:

Phenotypic Screening Sets: Format/SizeDescriptionsDownload
Phenotypic Pre-Plated Set14320 compounds
Pre-Plated Set
Amount: 0.01-2.0 mg
Update: 2017-03
ASINEX has created a diverse set of molecules by applying strict physico-chemical and structural descriptors to ensure good solubility and permeability properties. For more information, please download >>>sdf-icon pdf-icon
SL#004
Oncology Phenotypic Screening-1
(Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Release: 2016
ASINEX's oncology-oriented phenotypic library includes compounds based on several scaffolds with proven cytotoxicity (sub-µM EC50 in MTT assay) against a number of cancer cell lines: MV-411 (acute monocytic leukemia), HCT-116 (human colon cancer), MCF-7 (human breast adenocarcinoma‎), A-172 (Human glioblastoma), COLO-320 (colorectal adenocarcinoma), U-937 (histiocytic lymphoma), A-375 (malignant melanoma), BXPC-3 (pancreas adenocarcinoma), U118-MG (malignant glioma), and LN-229 (glioblastoma). Some active compounds were screened in a biochemical assay showing nM level of IC50 against several kinases: Aurora A, Haspin, VEGFR, EGFR, PDGFR. For more information, please download >>>sdf-icon pdf-icon
SL#023
Oncology Phenotypic Screening-2
(Colon Cancer/Non-Macrocycle)
80 compounds / set
Pre-Plated Set
Release: 2016
ASINEX has evaluated the susceptibility of several colon cancer cell lines (HCT-116, SW-620, COLO-320, RKO) to a diverse array of small molecules and identified a series of related compounds that kill cancer cells at sub-µM concentrations with limited off target effect on healthy cells (human fibroblasts). Additional screening in a cell-based luciferase reporter assay of Wnt signaling has provided preliminary evidence of Wnt-dependent mechanism of action. For more information, please download >>>sdf-icon pdf-icon
SL#035
Oncology Phenotypic Screening-3
(Macrocycles)
80 compounds / set
Pre-Plated Set
Release: 2016
ASINEX has evaluated the susceptibility of several cancer cell lines (i.e. RKO, HCT116, Molt-4, Rs4-11, U937, A549, H1568, H23, PANC1, A2780) to an array of peptidic and non-peptidic macrocycles and identified a series of compounds that kill cancer cells at µM concentrations. For more information, please download >>>sdf-icon pdf-icon

Please click here for List of all Signature Libraries.

Top